← Back to headlines
Eli Lilly slips as Novo to cut list prices for GLP-1 drugs
Eli Lilly's stock declined after its competitor, Novo Nordisk, announced plans to reduce the list prices for its GLP-1 class of drugs.
24 Feb, 13:12 — 24 Feb, 13:12
ℹOnly 1 source covers this story
